Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.910
-0.020 (-1.04%)
At close: Mar 28, 2025, 4:00 PM
1.890
-0.020 (-1.05%)
Pre-market: Mar 31, 2025, 9:19 AM EDT

Akebia Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Market Capitalization
451415234106395405
Upgrade
Market Cap Growth
77.46%77.46%120.08%-73.16%-2.30%-46.16%
Upgrade
Enterprise Value
588484301121363241
Upgrade
Last Close Price
1.911.901.240.582.262.80
Upgrade
PS Ratio
2.522.591.200.361.871.37
Upgrade
PB Ratio
-9.17-8.43-7.6420.305.341.63
Upgrade
P/TBV Ratio
-----8.36
Upgrade
EV/Sales Ratio
3.673.021.550.411.710.82
Upgrade
EV/EBITDA Ratio
--39.44--
Upgrade
Debt / Equity Ratio
-3.84-3.84-4.7230.072.560.51
Upgrade
Debt / EBITDA Ratio
---18.82--
Upgrade
Asset Turnover
0.690.690.650.660.360.42
Upgrade
Inventory Turnover
1.641.642.130.771.670.72
Upgrade
Quick Ratio
1.071.070.821.010.791.59
Upgrade
Current Ratio
1.411.411.181.431.041.99
Upgrade
Return on Equity (ROE)
----237.83%-175.37%-119.82%
Upgrade
Return on Assets (ROA)
-12.49%-12.49%-9.30%-4.89%-24.27%-15.41%
Upgrade
Return on Capital (ROIC)
-22.81%-22.81%-20.14%-10.17%-44.71%-24.88%
Upgrade
Earnings Yield
-15.38%-16.74%-22.23%-88.77%-71.32%-95.09%
Upgrade
FCF Yield
-9.02%-9.82%-10.01%-69.03%-63.99%-27.35%
Upgrade
Buyback Yield / Dilution
-12.53%-12.53%-2.56%-10.14%-19.85%-16.95%
Upgrade
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q